SLC2A1 and melanoma: Metabolic cancer therapies have numerous specific metabolic targets and so far, studies into the correlation between melanoma expression of specific glycolytic transporters and enzymes, such as GLUT1 and hexokinase (HK), and 18F-FDG uptake are limited and contradictive [31, 32].